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Chromosome 9p21Risk alleles within a gene desert at the 9p21 locus constitute the most prevalent genetic determinant of
cardiovascular disease. Previous research has demonstrated that 9p21 risk variants inﬂuence gene
expression in vascular tissues, yet the biological mechanisms by which this would mediate atherosclero-
sis merits further investigation. To investigate possible inﬂuences of this locus on other tissues, we
explored expression patterns of 9p21-regulated genes in a panel of multiple human tissues and found
that the tumor suppressor CDKN2B was highly expressed in subcutaneous adipose tissue (SAT). CDKN2B
expression was regulated by obesity status, and this effect was stronger in carriers of 9p21 risk alleles.
Covariation between expression of CDKN2B and genes implemented in adipogenesis was consistent with
an inhibitory effect of CDKN2B on SAT proliferation. Moreover, studies of postprandial triacylglycerol
clearance indicated that CDKN2B is involved in down-regulation of SAT fatty acid trafﬁcking. CDKN2B
expression in SAT correlated with indicators of ectopic fat accumulation, including markers of hepatic
steatosis. Among genes regulated by 9p21 risk variants, CDKN2B appears to play a signiﬁcant role in
the regulation of SAT expandability, which is a strong determinant of lipotoxicity and therefore might
contribute to the development of atherosclerosis.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Manifestations of atherosclerosis such as myocardial infarction
and stroke are leading causes of death worldwide [1]. Beside envi-
ronmental factors including lifestyle, the risk of cardiovascular dis-
ease (CVD) is also inﬂuenced by genetic variation, and several
genomic regions have been linked to CVD [2]. The strongest of
these is located on chromosome 9p21, where single-nucleotide
polymorphisms (SNPs) located within a 53-kilobase interval have
shown consistent and strong association with CVD [3–7].The 9p21 locus confers CVD risk through a mechanism which
appears to be independent from conventional risk factors, includ-
ing dyslipidaemia, hypertension, and impaired glucose metabolism
[5,8–10]. However, a recent study indicated that the effect of risk
variants is modiﬁed by diet [11].
Most of the CVD-associated SNPs within the 9p21 locus are lo-
cated in a so-called gene desert – a genomic region devoid of pro-
tein-coding genes. Recent studies of gene expression in vascular
tissues or peripheral mononuclear blood cells demonstrate that
the 9p21 disease variants may be involved in the regulation of
nearby genes, including cyclin-dependent kinase inhibitor 2A/B
(CDKN2A), CDKN2B and antisense noncoding RNA in the INK4 locus
(ANRIL) [12–17]. However, the reported associations between risk
variants and gene expression appear somewhat conﬂicting, as re-
viewed by Cunnington & Keavney [18]. One reason for this may
be that the CVD risk SNPs affect the expression of ANRIL, which
in turn may affect expression of other nearby genes via epigenetic
mechanisms [19].
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in vascular tissues has been found, the biological mechanisms that
would link this to human atherosclerosis development are still not
fully elucidated. Studies in humans and in mice models have
shown that vascular mechanisms, such as smooth muscle cell pro-
liferation [20], response to inﬂammatory signaling [21] and macro-
phage phagocytosis [22], may be involved. However, the CVD-
associated variants at the 9p21 locus may affect the expression
of adjacent genes also in extravascular tissues. We therefore ex-
plored the possible regulatory inﬂuences of this locus in human tis-
sues not previously studied in this context and subsequently
assessed the ﬁndings in carefully phenotyped cohorts.
2. Materials and methods
All subjects gave written informed consent prior to inclusion in
the study. The studies were conducted in accordance with the Dec-
laration of Helsinki and were approved by the local ethics
committees.
2.1. Study populations
The Sibpair study includes 154 Swedish nuclear families re-
cruited via BMI-discordant adult sibling pairs (BMI difference
P10 kg/m2) as described previously [23]. Subjects underwent
extensive phenotypic examinations. In the current analysis, gene
expression data were available for 354 adult sibs (106 males) from
151 families. BMI ranged from 16.9 to 57.5 kg/m2 (Supplementary
Table II).
Lean and obese women from UK undergoing elective surgery
were recruited and abdominal subcutaneous and omental adipose
tissue biopsies were obtained [24] (Supplementary Table II).
Obese Swedish subjects underwent 18 weeks of caloric restric-
tion by means of very-low calorie diets [25]. Subcutaneous adipose
tissue biopsies were taken at baseline, week 8, and week 18 from a
subset of 10 subjects (Supplementary Table II).
2.2. DNA microarray analysis
Adipose tissue RNA preparation and microarray analysis (U133
plus 2.0 microarrays, Affymetrix, Santa Clara, CA, USA) were per-
formed as previously described [26].
2.3. Real-time PCR analysis
RNA was reverse transcribed using the High Capacity cDNA RT
kit (Applied Biosystems, Foster City, CA, USA). Reagents for real-
time PCR analysis of CDKN2B (Hs00793225_m1), LPR10
(Hs00204094_m1), and PPIA (Hs99999904_m1) were purchased
from Applied Biosystems and used according to the manufacturer’s
protocol.
2.4. Genotyping
DNA was isolated from whole blood and genotyping of the
rs10757278 and rs2383207 was performed using the TaqMan-
based system (Applied Biosystems) and assays (C_11841860_10
and C_15789010_10). Successful genotypes were obtained from
95.2% for rs10757278 and 96.7% for rs2383207.
2.5. Body composition
A subset (n = 137) from the Sibpair study underwent computed
tomography measurements of body composition. Visceral and sub-
cutaneous fat were estimated from a scan at the level of the iliaccrest. Leg subcutaneous and intermuscular fat were estimated at
the mid-thigh level. Tissue areas were determined as previously
described [27].
2.6. Intravenous glucose tolerance test and biochemistry
Frequent-sampling intravenous glucose tolerance test was per-
formed in the Sibpair cohort for the assessment of insulin sensitiv-
ity (SI) and disposition index (DI), and blood biochemistry was
performed as previously described [26].
2.7. Postprandial lipid metabolism
Postprandial triacylglycerol (TAG) clearance in subjects of the
Sibpair study was measured in serum drawn in the fasting state
and hourly for seven hours after ingestion of a standard meal com-
posed of 41.3 g protein (22% of energy content), 46.3 g fat (54%),
and 46.8 g carbohydrates (25%), corresponding to 769 kcal. Clear-
ance was expressed as area under the curve, adjusted for fasting
value.
2.8. Statistical analysis
Statistical analyses were performed using the SAS software
package (v. 9.1.3, SAS Institute Inc, Cary, NC, USA). Quantitative
data were transformed towards normal distribution using Box-
Cox power transformations. Outliers beyond 3 standard deviations
from the trait mean were excluded. Additional statistical analyses
are described in the Method supplement.
3. Results
3.1. CDKN2B is highly expressed in adipocytes
The expression of 9p21 positional candidate genes ANRIL,
CDKN2A, CDKN2B, and MTAP were analyzed by microarray in a pa-
nel of 65 human tissues. The CDKN2B gene showed the highest
expression in subcutaneous adipose tissue (SAT) whereas the other
positional candidate genes displayed low signals in all tissues
investigated (Fig. S1). The tissue distribution pattern of CDKN2B
expression was also investigated by real-time PCR in a subset of
tissues and cells. In this analysis, the highest expression of CDKN2B
was observed in subcutaneous adipocytes (Fig. 1A). In view of the
association between obesity and CVD, which is independent of
conventional CVD risk factors [28], we pursued the investigation
of CDKN2B expression in adipose tissue further.
3.2. Adipose tissue CDKN2B expression varies among fat depots and is
regulated by energy balance
Given that different adipose tissue depots have varying inﬂu-
ences on the metabolism [29], CDKN2B expression was investi-
gated in paired SAT and omental adipose tissue biopsies (n = 10)
by microarray. Higher expression in SAT compared to omental adi-
pose tissue was found in both lean (3.2-fold, P = 0.004) and obese
(2.9-fold, P = 0.028) subjects (Fig. 1B).
A correlation between BMI and SAT CDKN2B expression was
found in the Sibpair study (r = 0.46, P = 6.3  1020) (see Fig. 2A).
This ﬁnding was conﬁrmed by real-time PCR in a small set of SAT
and subcutaneous adipocyte samples (Fig. 1C).
Next, we investigated whether CDKN2B expression in SAT is
regulated by weight loss following 18 weeks of severe caloric
restriction in ten obese individuals. A mean weight loss of 28.4
(range 21.0–38.6) kilograms induced decreased CDKN2B expres-
sion (Fig. 1D, P = 0.001).
Fig. 1. Expression of CDKN2B in multiple human tissues and covariation of CDKN2B expression in subcutaneous adipose tissue with energy balance. (A) CDKN2B expression
analyzed by RT-PCR in adipocytes (n = 3) and adipose tissue (n = 3) from healthy volunteers together with 18 other human tissues from the Human Total RNA Master Panel II.
CDKN2B expression was normalized to reference gene PPIA. Values are mean ± SEM, when applicable. (B) Comparison of CDKN2B expression, analyzed by DNA microarray,
between omental (om) and subcutaneous (sc) adipose tissue among lean and obese subjects. P values are from paired T tests of differences between fat depots. (C)
Relationship between BMI and CDKN2B expression analyzed by RT-PCR in subcutaneous adipose tissue at the whole-tissue level and speciﬁcally in adipocytes from healthy
volunteers. The measurements are the same as in panel A. CDKN2B expression was normalized to reference gene PPIA. (D) Response in subcutaneous adipose tissue of CDKN2B
expression, analyzed by RT-PCR, to 8 and 18 weeks of caloric restriction in obese adults. CDKN2B expression was normalized to reference gene LRP10. P value is for repeated
measures ANOVA from a linear mixed model.
1128 P.-A. Svensson et al. / Biochemical and Biophysical Research Communications 446 (2014) 1126–11313.3. BMI-dependent association between 9p21 variants and adipose
tissue CDKN2B expression
CVD risk alleles at 9p21 locus have been shown to inﬂuence
CDKN2B expression and therefore the associations between risk al-
leles of the rs10757278 SNP and CDKN2B expression in SAT were
investigated in the Sibpair study. No direct association between
expression and risk allele carrier status was found. However, in a
model which adjusted for non-independence among relatives,
sex, age and BMI, a positive correlation between risk allele carrier
status and CDKN2B expression was found (P = 0.002). Moreover,
risk variant carrier status modiﬁed the previously described asso-
ciation between BMI and CDKN2B expression, yielding a steeper
slope in carriers of the risk allele, compared with non-carriers
(Fig. 2A) (P = 0.043 for rs10757278-by-BMI interaction). Similar re-
sults were obtained for the risk allele (G) of rs2383207, both for the
main effect (P = 0.0052) and for the interaction (P = 0.048).
3.4. Inverse relationship between expression of CDKN2B and genes
implicated in adipose tissue expandability
The known anti-proliferative effects of CDKN2B [30], its high
expression in SAT and its link to obesity suggest that this gene is
involved in the regulation of SAT growth and expandability in re-sponse to changes in energy balance. We sought further support
for this theory using the Sibpair study to examine expression
covariation between CDKN2B and genes implemented in various
aspects of adipose tissue expandability, such as adipogenesis, pro-
liferation and angiogenesis.
Among the genes whose expression correlated signiﬁcantly
with CDKN2B expression, 259 genes could be classiﬁed as having
promotive or inhibitory effects on adipose tissue expandability
(see Supplementary methods and Supplementary Table I). Aiming
to discern a global effect of CDKN2B on these 259 genes, we per-
formed an association analysis between the promotive or inhibi-
tory effects of the genes versus their positive or negative
correlation with CDKN2B expression. As shown in Fig. 2B, the
majority of promotive genes correlated negatively with CDKN2B,
whereas the majority of inhibitory genes correlated positively
with CDKN2B. Consistently, there were lower than expected fre-
quencies of promotive genes positively correlated and inhibitory
genes negatively correlated with CDKN2B expression (X2 = 30.9,
P = 2.7  108).
The classical initiator of adipogenesis, peroxisome proliferator-
activated receptor gamma [31], was negatively correlated with
CDKN2B, whereas adipogenesis inhibitors such as Cyclin D1 [32]
and WW domain containing transcription regulator 1 [33] were
positively correlated with CDKN2B.
Fig. 2. Covariation of CDKN2B expression in subcutaneous adipose tissue with cardiovascular risk alleles, adipose tissue regulatory genes, and postprandial lipid clearance. (A)
Data from the Sibpair study, showing the relationship between BMI and CDKN2B expression (microarray) in SAT from carriers of the rs10757278 risk allele (right) and non-
carriers (left), where the slope of the regression line is steeper for risk allele carriers compared to non-carriers (P < 0.05 for genotype-by-CDKN2B interaction). Dotted curves
indicate the 95-percent conﬁdence intervals for the regression lines. (B) Association analysis, in the Sibpair study, of 259 adipose transcripts analyzed by microarray with
promotive or inhibitory effects on tissue growth vs. their positive or negative correlation with CDKN2B expression. Triangles indicate expected counts under the null
hypothesis of no association. The P value denotes the signiﬁcance of a X2 test (X2 = 30.9; df = 1). (C) Data from the Sibpair study, showing lipid clearance from serum during 7 h
after a standardized meal (n = 225). Data are expressed as area under the curve (AUC) for postprandial serum triacylglycerol, categorized by CDKN2B expression tertile. Data
are represented as standard deviations from the overall mean. Error bars are ±standard errors. P value is for the effect of CDKN2B tertile on triacylglycerol AUC, adjusted for
fasting value, BMI, and non-independence among siblings as assessed by a linear mixed model.
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ogenesis genes were highly expressed in SAT and signiﬁcantly cor-
related with CDKN2B expression. Among antiangiogenic genes,
thrombospondin 1, caveolin 1 and 2 were positively correlated
with CDKN2B. Expression of important proangiogenic genes e.g.,
angiogenin and vascular endothelial growth factor A, were nega-
tively correlated with CDKN2B expression (Supplementary Table I).
3.5. Increased CDKN2B expression in SAT impedes postprandial lipid
clearance
Impairment of adipose tissue growth and lipid accommodation
manifests itself as ectopic lipid accumulation. Therefore, we inves-
tigated covariation of CDKN2B expression with clinical indicators of
a ‘‘lipodystrophic’’ phenotype.
One acute effect of such impairment, which can be studied in
the short term, is reduced clearance from serum of lipids derived
from the consumption of a meal. We measured postprandial triac-
ylglycerol (TAG) levels following a standardized meal in subjects
from the Sibpair study, subdivided into tertiles of SAT CDKN2B
expression. The results show that high adipose tissue CDKN2B
expression is linked to high postprandial TAG levels (Fig. 2C,
P = 0.0005). The effect of CDKN2B expression level was indepen-dent of BMI, which is a strong determinant of postprandial
lipidaemia.3.6. CDKN2B expression in SAT and ectopic lipid accumulation
Other indicators of lipodystrophy or lipotoxicity include the
abundance of visceral, intramuscular and hepatic fat, insulin resis-
tance, and impaired pancreatic beta cell function.
In a subset of the Sibpair cohort, we used computed tomogra-
phy to measure body composition at the iliac crest and mid-thigh
levels. These levels were chosen to obtain estimates of abdominal
subcutaneous vs. visceral adipose tissue (VAT) and extremity sub-
cutaneous vs. intermuscular adipose tissue, respectively. CDKN2B
expression was positively correlated with the majority of these
adipose tissue measurements (Table 1, model 1). Moreover, the
VAT/SAT ratio and the amount of SAT in the thigh correlated signif-
icantly to CDKN2B expression even after adjustment for BMI (Ta-
ble 1, model 2).
Using serum alanine aminotransferase (S-ALAT) as a marker
[34], we found evidence of a relationship between CDKN2B expres-
sion in SAT and hepatic steatosis, since S-ALAT was positively cor-
related with CDKN2B expression, also after BMI adjustment.
Table 1
Correlations of subcutaneous adipose tissue (SAT) CDKN2B expression with body-
composition and metabolic traits susceptible to the effects of ectopic lipid accumu-
lation or suppressed SAT lipid accommodation.
Phenotype Model 1 Model 2
r P-Value r P-Value
Computed tomography areas at iliac crest levela
Visceral adipose tissue 0.33 0.0003 0.07 0.472
Subcutaneous adipose tissue 0.24 0.028 0.06 0.500
VAT/SAT 0.19 0.007 0.26 0.002
Computed tomography areas at mid-thigh levela
Intermuscular adipose tissue 0.33 2.2  106 0.00 0.974
Subcutaneous adipose tissue 0.13 0.131 0.19 0.008
IMAT/SAT 0.29 0.0001 0.12 0.217
Hepatic steatosisb
S-ALAT 0.34 1.4  109 0.19 0.0008
Frequent-sampling intravenous glucose tolerance testc
Insulin sensitivity 0.40 4.3  1012 0.08 0.142
Disposition index 0.14 0.011 0.02 0.794
r = correlation coefﬁcient from a model adjusting for the non-independence among
siblings (model 1), and non-independence among siblings and BMI (model 2). VAT/
SAT = ratio of visceral to abdominal subcutaneous adipose tissue areas. IMAT/
SAT = ratio of thigh intermuscular to thigh subcutaneous adipose tissue areas. S-
ALAT = serum alanine aminotransferase.
a n = 137.
b n = 313.
c n = 326.
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The mechanism that links regulatory sequence variants within
the 9p21 gene desert with CVD has in recent years been intensely
investigated. Studies have suggested mechanisms in vascular tis-
sue that may contribute to this link [20–22]. Our study suggests
a new possible route how the 9p21 locus may affect CVD develop-
ment via alteration in adipose tissue CDKN2B expression.
We found that CDKN2B is highly expressed in SAT, and its
expression shows covariation with energy balance (higher expres-
sion in obese subjects and down-regulated expression during calo-
ric restriction-induced weight-loss). Considering the capability of
adipose tissue to expand and retract throughout life, it is not sur-
prising that a gene implemented in cell cycle regulation is variably
expressed in this tissue. In line with this, we observed a correlation
pattern between CDKN2B expression and expression of genes in-
volved in adipose tissue expandability, suggesting that CDKN2B
has an inhibitory effect on adipogenesis and SAT expandability. A
recent study by Horswell et al. has provided direct experimental
support to the hypothesis that CDKN2B is important for adipogen-
esis. They show that knock-down of Cdkn2b expression in a mouse
adipocyte cell line results in increased adipogenesis [35]. More-
over, we found substantially higher CDKN2B expression in subcuta-
neous than in visceral adipose tissue, suggesting a larger restraint
on the proliferative capacity and adipogenesis of the former com-
pared to the latter, which might contribute to their altered relative
abundances.
Inadequate SAT expandability and fat storage capacity is the
disease-causing mechanism behind lipodystrophy syndromes. It
has been proposed that the dysmetabolic consequences of severe
obesity are partly attributable to ‘‘acquired lipodystrophy’’ which
develops as the adipocytes reach their maximal capacity to accom-
modate dietary lipids, causing lipid accumulation in visceral fat de-
pots and non-adipose tissues [36]. McQuaid et al. observed that
obese men, despite substantially greater adipose tissue mass,
showed depressed adipose tissue fat storage capacity compared
with lean controls [37].
Several studies have investigated the link between CVD risk
SNPs at the 9p21 locus and expression of CDKN2B in vascular tissueand leukocytes. However, the results from these studies are con-
ﬂicting [18]. This may partially be due to the risk variant inﬂuence
on the expression of ANRIL, which in turn may affect CDKN2B
expression via epigenetic mechanisms [19]. In addition, confound-
ers such as age and BMI were not always accounted for. We found a
BMI dependent association between risk allele carrier status and
CDKN2B expression in adipose tissue. More importantly, the risk
variants modiﬁed the correlation between BMI and CDKN2B
expression, suggesting that the expandability of SAT in risk allele
carriers is reduced. Visel et al. [38] showed that deletion of a 70-
kilobase noncoding region on mouse chromosome 4, orthologous
to the human 9p21 CVD risk interval resulted in reduced Cdkn2a
and Cdkn2b expression. Compared to the wild type, a faster weight
gain was seen in mice lacking this region, whereas a difference in
aortic fatty-lesions after high fat diet could not be shown. In view
of our ﬁndings, the results may be interpreted in terms of reduced
lipotoxicity due to loss of Cdkn2b-mediated inhibition of SAT. How-
ever, a recent study showed that Cdkn2b deﬁcient mice on an ApoE
deﬁcient background develop more atherosclerosis compared to
ApoE deﬁcient mice with an intact Cdkn2b gene [22].
Our study lacked statistical power to assess direct associations
between CVD risk alleles and lipotoxicity phenotypes. A large
study on two independent human cohorts, showed signiﬁcant
interaction between unhealthy diet and 9p21 risk alleles on CVD,
whereas carrier status did not affect risk in subjects on healthier
diet [11]. Those results are consistent with ours, which showed
higher postprandial TAG in subjects with high CDKN2B expression,
which in turn was higher in 9p21 risk allele carriers. Relevant to
our ﬁndings and their proposed contribution to CVD risk, postpran-
dial lipid dysmetabolism has been shown to independently predict
CVD [39–41]. The reason that the CVD risk of the 9p21 locus have
been shown to be independent of dyslipidaemia may be due to that
only fasting blood lipid levels have been investigated.
Based on our ﬁndings, we propose that CDKN2B is involved in
the regulation of SAT in response to changes in energy balance.
This study suggests that 9p21 risk alleles contribute to CVD risk
indirectly via inhibition of adipogenesis and adipose tissue
expandability which may promote ectopic fat accumulation.
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